Medicines Patent Pool Sample Clauses

Medicines Patent Pool. Medicines Patent Pool By Name: Xxxxxxx Xxxx Title: Executive Director Licensee: By Name: Rabbur Reza Title: Chief Operating Officer Appendix 1 Compound Appendix 2 Patents Country Patent Type Status App No. Filing Date Title A.R.I.P.O. Compound Filed AP/P/2021/013602 06-Aug-2021 Nitrile-Containing Antiviral Compounds Algeria Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Argentina Compound Filed P210102205 06-Aug-2021 Nitrile-Containing Antiviral Compounds Aruba Compound Filed Awaiting 06-Aug-2021 Nitrile-Containing Antiviral Compounds Australia Compound Filed 2021266232 06-Aug-2021 Nitrile-Containing Antiviral Compounds Bahamas Compound Docketed Nitrile-Containing Antiviral Compounds Bahrain Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Bangladesh Compound Filed 248/2021 08-Aug-2021 Nitrile-Containing Antiviral Compounds Barbados Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Bolivia Compound Filed SP-000165-2021 09-Aug-2021 Nitrile-Containing Antiviral Compounds Brazil Compound Filed BR112021022419-0 06-Aug-2021 Nitrile-Containing Antiviral Compounds Canada Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Chile Compound Filed 202102965 06-Aug-2021 Nitrile-Containing Antiviral Compounds China P.R. Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Colombia Compound Filed NC2021/0015067 06-Aug-2021 Nitrile-Containing Antiviral Compounds Costa Rica Compound Filed 2021-0558 06-Aug-2021 Nitrile-Containing Antiviral Compounds Cuba Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Dominican Republic Compound Filed P2021-0232 06-Aug-2021 Nitrile-Containing Antiviral Compounds Ecuador Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Egypt Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds El Salvador Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Eurasian Patent Convention Compound Filed 202192798 06-Aug-2021 Nitrile-Containing Antiviral Compounds European Patent Convention Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Georgia Compound Filed 15794/1 06-Aug-2021 Nitrile-Containing Antiviral Compounds Guatemala Compound Filed A-2021-00229 06-Aug-2021 Nitrile-Containing Antiviral Compounds Honduras Compound Filed HN/...
AutoNDA by SimpleDocs
Medicines Patent Pool. Medicines Patent Pool By Name:Xxxxxxx Xxxx Title: Licensee: Executive Director Shanghai Xxxxxx Bio-Pharmaceutical Co., Ltd. By Name: Ms An Xiaoxia Title: President Appendix 1 - Countries in the Territory LIC : Low Income Country LDC : Least Developed Country (UN Classification) SSA : Sub-Saharan Africa LMIC : Lower Middle-Income Country UMIC : Upper Middle-Income Country LIC+LDC+SSA # Country Channels in scope of Agreement 1 Afghanistan All 2 Angola All 3 Bangladesh All 4 Benin All 5 Bhutan All 6 Botswana All
Medicines Patent Pool. By------------- Name: Title: LICENSEE: [Licensee] By------------- Name: Title: Exhibit A Territory Afghanistan Eritrea Angola Ethiopia Antigua and Barbuda Fiji Bangladesh Gabon Belize Gambia enin Georgia Bhutan Ghana Bolivia Grenada Botswana Guadeloupe Burkina Faso Guinea Burundi Guinea-Bissau Cambodia Guyana Cameroon Haiti Cape Verde Indonesia Central African Republic Xxxxxx Xxxx Kenya Comoros Kiribati Cook Island Laos Cote d'Ivoire Lesotho Democratic Republic of Liberia the Congo Libya Congo, Rep. Madagascar Djibouti Malawi Dominica Maldives Egypt Mali Equatorial Guinea Xxxxxxxx Islands Mauritania Mauritius Micronesia M rocco Mozambique Myanmar Namibia Nauru Nepal Nevis Niger Nigeria Niue Pakistan Palau Papua New Guinea Philippines Reunion Islands Rwanda Saba Saint Xxxxxxxxxxx and Kitts Saint Eustatius Saint Lucia Saint Xxxxxxx & the Grenadines Samoa Sao Tome and Principe Senegal Sefichelles Sierra Xxxxx Xxxxxxx Islands Somalia South Africa South Sudan Sri Lanka Suriname Swaziland Tanzania Timor-Leste Togo Tunisia Turkmenistan Tuvalu Uganda Vanuatu Vietnam West Bank and Gaza Yemen Zambia Zimbabwe India Exhibit B Manufacturing-Only Countries
Medicines Patent Pool. Medicines Patent Pool By Name: Xxxxxxx Xxxx Title: Executive Director Licensee: By Name: Title: Dr.Xxxxx Xxxxx Head - Rx India Business LICENSEE: CIPLA LIMITED By Name: Xxxx Xxxxxxxx Title: Chief Financial Office, India Business DocuSign Envelope ID: 91216EB2-F486-414B-B694-F90CEB5F065E

Related to Medicines Patent Pool

  • Patent Rights The State and the U. S. Department of Transportation shall have the royalty free, nonexclusive and irrevocable right to use and to authorize others to use any patents developed by the Engineer under this contract.

  • Patent Marking LICENSEE shall xxxx all Licensed Products made, used or sold under the terms of this Agreement, or their containers, in accordance with the applicable patent marking laws.

  • Patent/Copyright Materials/Proprietary Infringement Unless otherwise expressly provided in this Contract, Contractor shall be solely responsible for clearing the right to use any patented or copyrighted materials in the performance of this Contract. Contractor warrants that any software as modified through services provided hereunder will not infringe upon or violate any patent, proprietary right or trade secret right of any third party. Contractor agrees that, in accordance with the more specific requirement contained in paragraph 18 below, it shall indemnify, defend and hold County and County Indemnitees harmless from any and all such claims and be responsible for payment of all costs, damages, penalties and expenses related to or arising from such claim(s), including, but not limited to, attorney’s fees, costs and expenses.

  • Patent Infringement A. The Contractor shall report to OC Public Works, promptly and in reasonable detail, each notice or claim of patent infringement based on the performance of this Contract of which the Contractor has knowledge.

  • ROYALTIES AND PATENTS The Contractor shall pay all royalties and license fees. The Contractor shall defend all suits or claims for infringement of any patent rights and shall save the State harmless from loss on account thereof, except that the State shall be responsible for all such loss when a particular design, process or the product of a particular manufacturer or manufacturers is specified, but if the Contractor has reason to believe that the design, process or product specified is an infringement of a patent, The Contractor shall be responsible for such loss unless he promptly gives such information to the Architect.

  • NOTICE AND ASSISTANCE REGARDING PATENT AND COPYRIGHT INFRINGEMENT The provisions of this clause shall be applicable only if the amount of this Agreement exceeds $100,000.

  • SOURCE CODE ESCROW FOR LICENSED PRODUCT If Source Code or Source Code escrow is offered by either Contractor or Product manufacturer or developer to any other commercial customers, Contractor shall either: (i) provide Licensee with the Source Code for the Product; or (ii) place the Source Code in a third party escrow arrangement with a designated escrow agent who shall be named and identified to the State, and who shall be directed to release the deposited Source Code in accordance with a standard escrow agreement acceptable to the State; or (iii) will certify to the State that the Product manufacturer/developer has named the State, acting by and through the Authorized User, and the Licensee, as a named beneficiary of an established escrow arrangement with its designated escrow agent who shall be named and identified to the State and Licensee, and who shall be directed to release the deposited Source Code in accordance with the terms of escrow. Source Code, as well as any corrections or enhancements to such source code, shall be updated for each new release of the Product in the same manner as provided above and such updating of escrow shall be certified to the State in writing. Contractor shall identify the escrow agent upon commencement of the Contract term and shall certify annually that the escrow remains in effect in compliance with the terms of this clause. The State may release the Source Code to Licensees under this Contract who have licensed Product or obtained services, who may use such copy of the Source Code to maintain the Product.

  • Product ACCEPTANCE Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User(s) shall have thirty (30) days from the date of delivery to accept hardware products and sixty (60) days from the date of delivery to accept all other Product. Where the Contractor is responsible for installation, acceptance shall be from completion of installation. Failure to provide notice of acceptance or rejection or a deficiency statement to the Contractor by the end of the period provided for under this clause constitutes acceptance by the Authorized User(s) as of the expiration of that period. The License Term shall be extended by the time periods allowed for trial use, testing and acceptance unless the Commissioner or Authorized User agrees to accept the Product at completion of trial use. Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User shall have the option to run testing on the Product prior to acceptance, such tests and data sets to be specified by User. Where using its own data or tests, Authorized User must have the tests or representative set of data available upon delivery. This demonstration will take the form of a documented installation test, capable of observation by the Authorized User, and shall be made part of the Contractor’s standard documentation. The test data shall remain accessible to the Authorized User after completion of the test. In the event that the documented installation test cannot be completed successfully within the specified acceptance period, and the Contractor or Product is responsible for the delay, Authorized User shall have the option to cancel the order in whole or in part, or to extend the testing period for an additional thirty (30) day increment. Authorized User shall notify Contractor of acceptance upon successful completion of the documented installation test. Such cancellation shall not give rise to any cause of action against the Authorized User for damages, loss of profits, expenses, or other remuneration of any kind. If the Authorized User elects to provide a deficiency statement specifying how the Product fails to meet the specifications within the testing period, Contractor shall have thirty (30) days to correct the deficiency, and the Authorized User shall have an additional sixty (60) days to evaluate the Product as provided herein. If the Product does not meet the specifications at the end of the extended testing period, Authorized User, upon prior written notice to Contractor, may then reject the Product and return all defective Product to Contractor, and Contractor shall refund any monies paid by the Authorized User to Contractor therefor. Costs and liabilities associated with a failure of the Product to perform in accordance with the functionality tests or product specifications during the acceptance period shall be borne fully by Contractor to the extent that said costs or liabilities shall not have been caused by negligent or willful acts or omissions of the Authorized User’s agents or employees. Said costs shall be limited to the amounts set forth in the Limitation of Liability Clause for any liability for costs incurred at the direction or recommendation of Contractor.

  • PATENT AND COPYRIGHT INFRINGEMENT Siemens will, at its option and expense, defend or settle any suit or proceeding brought against Buyer based on an allegation that any Equipment or use thereof for its intended purpose constitutes an infringement of any Patent Cooperation Treaty country member’s patent or misappropriation of a third party’s trade secret or copyright in the country where the Equipment is delivered by Siemens. Buyer will promptly give Siemens written notice of the suit or proceeding and the authority, information, and assistance needed to defend the claims. Buyer shall not acknowledge any such third-party proceedings defined under this Article 16. Siemens shall have the full and exclusive authority to defend and settle such claim(s) and will pay the damages and costs awarded in any suit or proceeding so defended. Buyer shall not make any admission(s) which might be prejudicial to Siemens and shall not enter into a settlement without Siemens’ written consent. Siemens is not responsible for any settlement made without its prior written consent. If the Equipment, or any part thereof, as a result of any suit or proceeding so defended is held to constitute infringement, or its use by Buyer is enjoined, Siemens will, at its option and expense, either: (i) procure for Buyer the right to continue using said Equipment; (ii) replace it with substantially equivalent non-infringing Equipment; or (iii) modify the Equipment so it is non-infringing. Siemens will have no duty or obligation under this Article 16 if the Equipment is: (i) supplied according to Xxxxx's design or instructions and compliance therewith has caused Siemens to deviate from its normal course of performance; (ii) modified by Buyer or its contractors after delivery; or (iii) combined by Buyer or its contractors with devices, methods, systems or processes not furnished hereunder and by reason of said design, instruction, modification, or combination a suit is brought against Buyer. In addition, if by reason of such design, instruction, modification or combination, a suit or proceeding is brought against Siemens, Buyer must protect Siemens in the same manner and to the same extent that Siemens has agreed to protect Buyer under this Article 16. THIS ARTICLE 16 IS AN EXCLUSIVE STATEMENT OF SIEMENS’ DUTIES AND BUYER’S REMEDIES RELATING TO PATENTS, TRADE SECRETS AND COPYRIGHTS, AND DIRECT OR CONTRIBUTORY INFRINGEMENT THEREOF.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

Time is Money Join Law Insider Premium to draft better contracts faster.